No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD20 positive	Childhood B Acute Lymphoblastic Leukemia	CD20 positive	Childhood B Acute Lymphoblastic Leukemia	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1
ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SH2B3 alteration	Childhood B Acute Lymphoblastic Leukemia	SH2B3 alteration	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
EPOR rearrangement	Childhood B Acute Lymphoblastic Leukemia	EPOR rearrangement	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + nelarabine Sensitive : A2	cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + nelarabine Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
KRAS mutation	Childhood B Acute Lymphoblastic Leukemia	KRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
CD20 expression	Childhood B Acute Lymphoblastic Leukemia	CD20 expression	Childhood B Acute Lymphoblastic Leukemia	rituximab + bortezomib Sensitive: C3 – Early Trials rituximab + bortezomib Sensitive : C3	rituximab + bortezomib Sensitive: C3 – Early Trials rituximab + bortezomib Sensitive : C3
PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	PDGFRB fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: C3 – Early Trials dasatinib Sensitive : C3	dasatinib Sensitive: C3 – Early Trials dasatinib Sensitive : C3
HER-2 expression	Childhood B Acute Lymphoblastic Leukemia	HER-2 expression	Childhood B Acute Lymphoblastic Leukemia	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
PAX5 fusion	Childhood B Acute Lymphoblastic Leukemia	PAX5 fusion	Childhood B Acute Lymphoblastic Leukemia	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
KMT2A rearrangement	Childhood B Acute Lymphoblastic Leukemia	KMT2A rearrangement	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
SNX2-ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	SNX2-ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Resistant: C4 – Case Studies dasatinib Resistant : C4	dasatinib Resistant: C4 – Case Studies dasatinib Resistant : C4
MLL rearrangement	Childhood B Acute Lymphoblastic Leukemia	MLL rearrangement	Childhood B Acute Lymphoblastic Leukemia	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
CD9 expression	Childhood B Acute Lymphoblastic Leukemia	CD9 expression	Childhood B Acute Lymphoblastic Leukemia	KBA1412 Sensitive: D – Preclinical KBA1412 Sensitive : D	KBA1412 Sensitive: D – Preclinical KBA1412 Sensitive : D
FOXO1 underexpression	Childhood B Acute Lymphoblastic Leukemia	FOXO1 underexpression	Childhood B Acute Lymphoblastic Leukemia	cyclophosphamide Resistant: D – Preclinical cyclophosphamide Resistant : D	cyclophosphamide Resistant: D – Preclinical cyclophosphamide Resistant : D
FOXO1 underexpression	Childhood B Acute Lymphoblastic Leukemia	FOXO1 underexpression	Childhood B Acute Lymphoblastic Leukemia	prednisone Resistant: D – Preclinical prednisone Resistant : D	prednisone Resistant: D – Preclinical prednisone Resistant : D
IGH-CRLF2 fusion + JAK2 R867Q	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion + JAK2 R867Q	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
JAK1 S646F	Childhood B Acute Lymphoblastic Leukemia	JAK1 S646F	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
IGH-CRLF2 fusion	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D

Childhood B Acute Lymphoblastic Leukemia

Associations(37)

Associations
(37)